

AMENDMENT




In the Claims:






The following listing of claims will replace all prior versions and listings of the claims in the application:


Listing of the Claims:

1.-14. (Cancelled.)

15. (Currently Amended) A method for inhibiting inflammation in a subject caused or contributed to by PMN migration across columnar epithelia and inflammation in a subject comprising, administering to a subject an effective amount of a lipoxin A₄ compound, wherein the lipoxin compound is an analog of natural lipoxin A₄, and wherein the analog of natural lipoxin A₄ has a metabolic transformation region different from the natural lipoxin A₄ resulting in a longer half-life than natural lipoxin A₄ selected from:







where R' is H or CH₃.

16-28. (Cancelled)